NeonMind Biosciences Inc.
The Issuer is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Issuer operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
NeonMind Biosciences Inc. (NEON)
Le 29 decembre/December 2020
The common shares of Neonmind Biosciences Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.
The Issuer is conducting research into potentially therapeutic uses of compounds found in psychedelic mushrooms and is commercializing edible mushroom infused beverages.